Published in Int J Mol Sci on December 03, 2015
Trends in research on indoor radon exposure and lung cancer in South Korea. Ann Occup Environ Med (2016) 1.40
Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther (2016) 0.77
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. BMC Cancer (2016) 0.77
Challenges of Identifying Clinically Actionable Genetic Variants for Precision Medicine. J Healthc Eng (2016) 0.76
Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure. Ann Occup Environ Med (2016) 0.75
GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data. BMC Bioinformatics (2017) 0.75
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget (2016) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Cancer genome landscapes. Science (2013) 25.33
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) (1993) 22.41
A sequencing method based on real-time pyrophosphate. Science (1998) 21.21
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) (2012) 20.08
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med (2015) 16.87
Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A (2002) 13.58
Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat (2000) 13.25
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet (1998) 9.84
Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci U S A (1992) 9.15
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Unbiased whole-genome amplification directly from clinical samples. Genome Res (2003) 6.29
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
ACMG clinical laboratory standards for next-generation sequencing. Genet Med (2013) 5.30
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genomics (2006) 4.55
Characterizing and measuring bias in sequence data. Genome Biol (2013) 4.39
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res (2004) 3.37
LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res (2012) 2.46
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn (2013) 2.27
Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. Genome Res (2004) 2.22
Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer (2014) 1.76
DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One (2013) 1.57
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res (2014) 1.50
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat (2006) 1.49
Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex whole genome amplified DNA generated from multiple DNA sources. Hum Mutat (2005) 1.42
Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance. BMC Biotechnol (2005) 1.36
DNA quantification of whole genome amplified samples for genotyping on a multiplexed bead array platform. Cancer Epidemiol Biomarkers Prev (2007) 1.31
Rubicon Genomics, Inc. Pharmacogenomics (2002) 1.31
The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet (2013) 1.27
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med (2013) 1.23
Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. Clin Chem (2005) 1.17
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol (2009) 1.15
Investigating the utility of combining phi29 whole genome amplification and highly multiplexed single nucleotide polymorphism BeadArray genotyping. BMC Biotechnol (2004) 1.11
Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol (2008) 1.07
Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med (2011) 1.05
Single cell genome sequencing. Curr Opin Biotechnol (2011) 0.97
Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med Genomics (2014) 0.95
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Curr Drug Targets (2015) 0.95
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Target Oncol (2014) 0.90
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PLoS One (2015) 0.90
Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. J Hum Genet (2012) 0.81
Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Transl Respir Med (2014) 0.80
Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. Cancer Biol Ther (2014) 0.76